Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Dec;9(12):4863-4866.
doi: 10.21037/jtd.2017.11.105.

Why anti-PD1/PDL1 therapy is so effective? Another piece in the puzzle

Antonio Marchetti  1 , Alessia Di Lorito  1 , Fiamma Buttitta  1
Affiliations
Editorial

Why anti-PD1/PDL1 therapy is so effective? Another piece in the puzzle

Antonio Marchetti et al. J Thorac Dis. 2017 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
The scheme reports the expression of PD-1/PD-L1 on different immune cell types in tumor microenvironment. Activated CD8+ T cells exhibit PD1 receptor. CD4+ T helper cells release IFNy which induces the expression of PDL1 by tumor cells and tumor-associated macrophages (TAM), thus inhibiting activated T cells. Furthermore, PDL1 binding to PD1 expressed on TMA acts as a “don’t eat me” signal which results in a decrease of phagocytic activity. Therefore, PD1/PD-L1 inhibitors can be very effective, unlocking both CD8+ T cells and TAM anti-tumor activity.
See this image and copyright information in PMC

Comment on

References

    1. Marchetti A, Barberis M, Franco R, et al. Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors. J Thorac Oncol 2017;12:1654-63. 10.1016/j.jtho.2017.07.031 - DOI - PubMed
    1. Zheng X, Turkowski K, Mora J, et al. Redirecting tumor-associated macrophages to become tumoricidal effectors as a novel strategy for cancer therapy. Oncotarget 2017;8:48436-52. - PMC - PubMed
    1. Alvey C, Discher DE. Engineering macrophages to eat cancer: from "marker of self" CD47 and phagocytosis to differentiation. J Leukoc Biol 2017;102:31-40. 10.1189/jlb.4RI1216-516R - DOI - PMC - PubMed
    1. Willingham SB, Volkmer JP, Gentles AJ, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A 2012;109:6662-7. 10.1073/pnas.1121623109 - DOI - PMC - PubMed
    1. Gordon SR, Maute RL, Dulken BW, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature 2017;545:495-9. 10.1038/nature22396 - DOI - PMC - PubMed